Fabricio Souza

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Gilberto de Castro, Iveta Kudaba, Yi‐Long Wu et al. · Journal of Clinical Oncology · 2022 · 318 citations · Full text

Medicine, Oncology, Pharmacology +17

Combination of <i>N</i> ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis

Cláudia P. Oliveira, José Tadeu Stefano, Érika Rabelo Forte de Siqueira et al. · Hepatology Research · 2007 · 108 citations

Medicine, Pharmacology, Pharmacotherapy +17

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş et al. · New England Journal of Medicine · 2025 · 84 citations

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka et al. · Cancer Science · 2021 · 57 citations · Full text

Medicine, Oncology, Pharmacology +16

Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).

Delvys Rodríguez‐Abreu, Steven Powell, Maximilian J. Hochmair et al. · Journal of Clinical Oncology · 2020 · 25 citations

Medicine, Oncology, Pharmacology +16